Market Newsdesk

SHANDONG, China, Nov. 24, 2020 (GLOBE NEWSWIRE) — The spring of 2020 is different. A sudden epidemic has stopped us from all kinds of progress. The world is shrouded in the haze of the epidemic, and the COVID-19 epidemic has become a matter of concern to everyone. There is no doubt that the outbreak of this epidemic has brought a great blow to the world economy. In this context, “high efficiency” has become the overall demand of manufacturing and processing in several major industries such as heavy machinery, urban rail transit, high-speed rail and new energy etc. 

With its excellent performance, 10kW+ laser cutting machine has gradually become the darling of the market and has been adopted by the majority of metal processing enterprises. As one of the fastest-growing companies in the laser industry, Bodor Laser has also taken part in this activity. Bodor Laser’s 10kW+ products have become a representative of new productivity in the field of laser cutting by virtue of wider and deeper processing range, stronger cutting ability and higher processing efficiency. Since the Bodor laser 10kW+ laser cutting machine was put into the market, it has repeatedly created industry sales miracles.

Until the beginning of November 2020, the sales volume of Bodor Laser 10kW products have achieved 260 units, the sales of 20kW have exceeded 20 units, the 30kW equipment has reached the world’s first batch of contracts, and the world’s first 40kW laser cutting machine has achieved its world premiere at the same time.

On September 4th, the Bodor Laser’s 40kW ultra-high power fiber laser cutting machine made its global debut at the Bodor Laser Innovation and Research Center, in order to define the future pioneering posture and achieve a new high point in the laser cutting industry.

40kW can make laser cutting technology improve a big step as a whole, break more limitations of laser cutting processing, and make laser processing have a more extensive use scene. On the premise of improving the processing quality, the processing efficiency of 10kW fiber laser cutting has also been doubled, allowing end users to complete more business volume in the same time. In addition, the overall processing cost has also been greatly reduced, allowing terminal sheet metal processing users to reduce costs and generate income.

Now, the world’s first 40kW laser cutting machine has been unveiled, redefining laser cutting. Bodor Laser will take the 40kW global debut as the starting point, start a new round of technological revolution, provide better services for customers and create more and greater value for global metal processing enterprises.

(Note: Bodor Laser’s global sales and service network provides services for 150 countries on 6 continents)

Chi Han
[email protected]
+86 15668308452

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/a02c98e0-2f15-4cae-8add-b2419d07ee23

https://www.globenewswire.com/NewsRoom/AttachmentNg/dd31108e-7602-45da-9301-a418961b4dd5

Sercel
Awarded
Seismic Equipment
Contract
for

Saudi Mega
–
C
rew

Paris, France
–
November
24
,
20
20

CGG announced today that Sercel has won a major contract to supply land seismic equipment for a 3D mega-crew survey recently awarded to ARGAS in Saudi Arabia. The equipment selected includes a Sercel 508^XT seismic acquisition system of over 60,000 channels equipped with strings of SG-10 geophones and a fleet of over 30 Nomad 65 Neo all-terrain vibrator trucks with VE464 advanced vibrator electronics. ARGAS will acquire the long-term survey in a harsh desert environment from the end of Q1 2021 onwards.

This award marks the fifth 508^XT system to be deployed on a mega-crew survey in the Middle East in the last five years, strengthening Sercel’s already well-established base in the region. With over 75 systems deployed worldwide, the 508^XT is the industry’s most field-proven acquisition system for all types of challenging land surveys. When combined with Nomad 65 Neo vibrators and the VE464’s unique Smart LF function, it is the ideal choice for reaching the highest productivity levels while recording the best broadband seismic data.

Sophie Zurquiyah, CEO, CGG, said: “We are delighted that ARGAS has selected an extensive Sercel product portfolio to equip the mega-crew survey it was recently awarded in Saudi Arabia. As an experienced industrial manufacturer, Sercel is trusted by its customers for its reliability to deliver large volumes of high-performance seismic equipment and for accompanying them on their most challenging surveys with dedicated technical support.”

About CGG

CGG (


www.cgg.com


) is a global geoscience technology leader. Employing around 4,
0
00 people worldwide, CGG provides a comprehensive range of data, products, services and equipment that supports the discovery and responsible management of the Earth’s natural resources. CGG is listed on the Euronext Paris SA (ISIN: 0013181864).

Contacts
 

Attachment

• CGG – Press Release pdf version

Montrouge, France, November 24, 2020

DBV Technologies Announces Leadership Changes

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Dr. Hugh Sampson has decided to step down from his role as Chief Scientific Officer (CSO) at DBV, effective December 1, 2020, to return to his research program at the Jaffe Food Allergy Institute at Mount Sinai. While acting as CSO, Dr. Sampson continued his commitment to the food allergy community by directing his research lab, running a NIH-sponsored prevention trial, and seeing patients in clinical practice part-time.

Dr. Sampson will take on a new role as Scientific Adviser to the Chief Executive Officer and Chairman of DBV’s Scientific Advisory Board. In this capacity, he will remain involved in DBV’s ongoing development of epicutaneous immunotherapy (EPIT™).

After three years serving on DBV’s Scientific Advisory Board, Dr. Sampson joined DBV in 2015 to formally lead the Company’s global scientific efforts and explore potential new applications of investigational Viaskin™ for the treatment of food allergies and autoimmune disorders, and for the development of novel vaccines. Dr. Sampson is the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai and the Director Emeritus of the Jaffee Food Allergy Institute. He is a member of the National Academy of Medicine, past chair of the Section on Allergy & Immunology of the American Academy of Pediatrics and the past-president of the American Academy of Allergy, Asthma and Immunology.

“Hugh is universally regarded as a leader in medical research in food allergy and immunology. We’re honored that he has contributed his remarkable expertise to advancing the Viaskin™ platform and shaping the scientific approach to our potential food allergy treatments. Today’s announcement is part of a thoughtful transition process, and we are grateful that he will continue to be an integral part of our team in his new role,” said Daniel Tassé, DBV’s Chief Executive Officer. “I’d like to thank Hugh for his commitment to our pursuit of improving patient outcomes and his ongoing, steadfast leadership.”

“I have always been impressed by the dedication and energy of everyone at DBV, and it has been an honor for me to act as DBV’s Chief Scientific Officer for the past five years,” said Dr. Sampson. “I am proud of what DBV has accomplished in better understanding the biology of EPIT and its potential applications. Now is the right time for me to return to Mount Sinai and focus on my research programs in novel diagnostics and prevention of food allergy. We have worked with purpose to advance the potential behind the clinical profile of EPIT, and I am excited by the possibility that it may be a viable treatment option for millions of patients. I look forward to continuing to work with DBV to advance their efforts in my new capacity as Scientific Advisor to Daniel.”

About DBV Technologies

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Forward Looking Statements

This press release may contain forward-looking statements and estimates, including statements regarding the potential benefits of Viaskin Peanut, the Company’s continued development of epicutaneous immunotherapy, and the Company’s transition plans. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the Company’s products have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the impact of the COVID-19 pandemic. Furthermore, the timing of any action by any regulatory agency cannot be guaranteed. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, the Company’s Securities and Exchange Commission filings and reports, including in the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Investor Relations Contact

Anne Pollak
+ 1 (857) 529-2363
[email protected]

Media Contact

Angela Marcucci
+1 (646) 842-2393
[email protected]

Attachment

• PDF Version

• Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis
• Development program is currently jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI) until end of planned Phase Ia study

ALLSCHWIL, Switzerland, Nov. 24, 2020 (GLOBE NEWSWIRE) — Polyphor AG (SIX: POLN) today announced a funding agreement with the Cystic Fibrosis Foundation to advance clinical development of its novel class antibiotic, inhaled murepavadin, in cystic fibrosis (CF). Inhaled murepavadin is a highly potent and selective antibiotic against Pseudomonas aeruginosa, including multidrug resistant strains. CF is characterized by chronic bacterial infection and severe inflammation that lead to progressive deterioration in lung function.

Under the terms of the agreement, Polyphor will be awarded up to USD $3.3 million to fund a Phase Ib/IIa clinical trial of inhaled murepavadin, as a follow-up study to a Phase Ia study in healthy volunteers using eFlow® Technology nebulizer (PARI Pharma GmbH), which is planned to be initiated pending CTA (clinical trial application) approval. The Phase Ib/IIa trial in adults with CF, assessing safety and tolerability (both overall and local) of ascending doses of inhaled murepavadin, is planned to be initiated in Q4 2021 following completion of the Phase Ia study. The Cystic Fibrosis Foundation Therapeutics Development Network (TDN) will provide support for the overall clinical development path for inhaled murepavadin.

“Pseudomonas aeruginosa infection is a leading cause of lung function decline in people with cystic fibrosis and our novel class antibiotic, inhaled murepavadin, has the potential to change the treatment paradigm transforming patients’ lives,” said Gokhan Batur, Chief Executive Officer of Polyphor. “This is Polyphor’s second award from the Cystic Fibrosis Foundation, whose support had made possible nearly every cystic fibrosis-specific drug available today. The award will further encourage clinical development of inhaled murepavadin, and we would like to thank the Cystic Fibrosis Foundation for their trust and ongoing support.”

About inhaled murepavadin:

Polyphor’s inhaled murepavadin is currently being developed as a precision antibiotic specifically targeting chronic Pseudomonas aeruginosa, for the treatment of these infections in people with CF. It is the first member of the Outer Membrane Protein Targeting Antibiotics (OMPTA), a novel class of antibiotics which was discovered by Polyphor and the University of Zurich and displays a unique mode of action. Based on the data of the inhaled murepavadin preclinical program suggesting significantly higher safety margins (at least 5-10 times) versus the intravenous formulation, Polyphor is planning to initiate the clinical development program. Until the end of the planned Phase Ia study the program is jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI). Inhaled murepavadin is also part of the iABC project, a Europe-wide program dedicated to the development of inhaled antibiotics run by a consortium of leading lung specialists and research institutions in various European countries. The Cystic Fibrosis Foundation award will allow further development until the end of the Phase Ib/IIa study.

Infections remain a significant problem for people with CF who require novel treatment options, despite the availability of CFTR modulators. If approved for commercial use, inhaled murepavadin would be the first new class of antibiotics for Gram-negative pathogens in the last 50 years. It would also be potentially the first agent to target specifically Pseudomonas aeruginosa bacteria versus the current standard of care, broad spectrum inhaled antibiotics.

For further information please contact:

For Media:

Bernhard Schmid
LifeSci Advisors
+41 44 447 12 21
[email protected]

About Polyphor

Polyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company’s leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company’s lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.

Disclaimer

This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor’s results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (the “Company”) (CSE:MYCO | OTC:MYCOF) announces that its previously issued financial statements for the fiscal year ended December 31, 2019, and the three- and six-month periods ended March 31, 2020 and June 30, 2020, any corresponding management’s discussion and analyses (collectively, the “Restated Documents”) will be restated and reissued.

During the fiscal year ended December 31, 2019, the Company recognized intangible assets in connection with the acquisitions of Relyfe Brand, LLC, Tealief Brand, LLC, and Drink Fresh Water, LLC. Upon further review, the assets do not meet the definition of intangible assets for the purposes of international financial reporting standards and as a result will be recorded as transaction costs in the Company’s statement of loss and comprehensive loss. The Restated Documents will reflect this change in the accounting treatment of the assets acquired in these acquisitions. The effect of the restatements does not impact the Company’s ongoing operations or cash position.

The Company intends to file the Restated Documents on or before November 30, 2020, in conjunction with the filing of the financial statements for the nine-month period ended September 30, 2020. The Restated Documents will replace and supersede the respective previously-filed financial statements and management’s discussion and analysis for such periods (collectively, the “Previous Documents”). The Previous Documents should no longer be relied upon.

On behalf of the Board of Directors

MYDECINE INNOVATIONS GROUP INC.

Joshua Bartch
Chief Executive Officer
[email protected]

About
Mydecine
Innovations Group

Mydecine Innovations Group™ is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company’s worldrenowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada. Mydecine’s portfolio companies Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ position the company at the forefront of disruptive modern medicine.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

Forward-looking Information Statement

This news release may contain certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian and United States securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the
anticipated timing for the filing of the Restated Documents
, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon
a number of
assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.